

ASTRAZENECA PLC  
Form 6-K  
December 15, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of December 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes \_\_\_ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

15 December 2017 12:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES  
Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 14 December 2017, it was notified by Pascal Soriot, a Director of the Company, that, on 13 December 2017, Mr Soriot ceased to be beneficially interested in 40,148 Ordinary Shares of \$0.25 each in the Company, following the gift of those shares to family members for nil consideration.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name  
Pascal Soriot

2 Reason for the notification

a) Position/status  
Chief Executive Officer

b) Initial notification /Amendment  
Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name  
AstraZeneca PLC

b) LEI  
PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

# Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                                                             |                           |                                                        |           |
|-------------------------------------------------------------|---------------------------|--------------------------------------------------------|-----------|
| Description of the financial instrument, type of instrument |                           | Ordinary Shares of US\$0.25 each in AstraZeneca PLC    |           |
| a)                                                          | Identification code       | GB0009895292                                           |           |
| b)                                                          | Nature of the transaction | Gift of shares to family members for nil consideration |           |
| c)                                                          | Price(s) and volume(s)    | Price(s)                                               | Volume(s) |
|                                                             |                           | 0                                                      | 40,148    |
| Aggregated information                                      |                           | Not applicable - single transaction                    |           |
| d)                                                          | - Aggregated volume       |                                                        |           |
|                                                             | - Price                   |                                                        |           |
| e)                                                          | Date of the transaction   | 13 December 2017                                       |           |
| f)                                                          | Place of the transaction  | Outside a trading venue                                |           |

## About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

## Media Relations

|                  |           |                  |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                                                     |                            |                     |
|-----------------------------------------------------|----------------------------|---------------------|
| Rob Skelding                                        | UK/Global                  | +44 203 749<br>5821 |
| Matt Kent                                           | UK/Global                  | +44 203 749<br>5906 |
| Gonzalo Viña                                        | UK/Global                  | +44 203 749<br>5916 |
| Jacob Lund                                          | Sweden                     | +46<br>8 553 260 20 |
| Michele Meixell                                     | US                         | +1 302 885<br>2677  |
| Investor Relations                                  |                            |                     |
| Thomas Kudsk Larsen                                 |                            | +44 203 749<br>5712 |
| Craig Marks                                         | Finance, Fixed Income, M&A | +44 7881 615<br>764 |
| Henry Wheeler                                       | Oncology                   | +44 203 749<br>5797 |
| Mitchell Chan                                       | Oncology; Other            | +1 240 477<br>3771  |
| Christer Gruvris                                    | Brilinta; Diabetes         | +44 203 749<br>5711 |
| Nick Stone                                          | Respiratory; Renal         | +44 203 749<br>5716 |
| US toll free                                        |                            | +1 866 381<br>7277  |
| Adrian Kemp<br>Company Secretary<br>AstraZeneca PLC |                            |                     |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 15 December 2017

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary